Allogeneic 'off-the-shelf' SARS-CoV-2-specific adoptive T-cell therapy for refractory viral infection and end organ disease
{{output}}
Objectives: Despite the effective roll-out of COVID-19 vaccines, immunocompromised patients have a higher risk of morbidity and mortality following SARS-CoV-2 infection. Allogeneic adoptive T-cell immunotherapy is now established... ...
